Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with Chemoradiotherapy for Resected Head and Neck Cancer
NCT00084318Phase 2Completed
- Sponsor
- NRG Oncology
- Start
- Apr 2004
- Primary completion
- Mar 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of KL-140 in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by NRG Oncology. Primary endpoint: Disease-free Survival at 2 years. Started Apr 2004; status: completed.
02
Drugs
KL-140
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00084318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00084318.